Sun Pharmaceutical Industries issued a voluntary recall of its anti-depressant drug bupropion hydrochloride in the U.S., reports CNBC's Money Control.
The Indian drugmaker initiated the recall for the 200 milligram dosage form of the drug on Dec. 20 after it failed to meet dissolution specifications. About 11,618 bottles of bupropion hydrochloride were pulled from shelves, according to the report.
The Food and Drug Administration classified the recall as class-III, meaning the products violate FDA labeling or manufacturing rules, but are unlikely to cause any adverse health reactions.
More articles on supply chain:
Shifting drug production back to US could raise prices: 5 takeaways
5 ways to prepare your supply chain for a disaster
Mayo Clinic physician: A stripped down FDA would be 'chaotic'